XPOVIO (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the Therapeutic Goods Administration (TGA) of Australia for patients with relapsed and/or refractory multiple myeloma (R/R MM) and in tripleclass refractory R/R MM. XPOVIO is the first of a new class of SINE medicines to be made available to Australian patients with penta-refractory R/R MM on the Pharmaceutical Benefits Scheme (PBS). SHANGHAI and HONG KONG, Sept. 1, 2022 /PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that XPOVIO (selinexor) in combination with dexamethasone (Xd) has been PBS Listed for the treatment of adult patients with R/R MM who have received at least four prior lines of therapy and whose disease is refra
Bortezomib Improves Survival in Kids With Lymphoma medindia.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medindia.net Daily Mail and Mail on Sunday newspapers.
Final data from the UK Optimum trial shows drug combination significantly improves progression-free survival in patients with ultra-high risk newly diagnosed multiple myeloma or primary cell leukaemia.